MONCYTE Health

Patented assay quantifying individual differences in how cells take up and store lipids, read from white blood cells including monocytes — it predicts how well cholesterol-lowering drugs will work in a given patient. University of Helsinki spin-out (1/2024); partner in the €7.2M Horizon Europe FH-EARLY project on familial hypercholesterolaemia.

The row

Sector

Therapeutics & Diagnostics

Stage

Pre-revenue — No sales yet

Location

Helsinki

Founded

2023 (entered in the trade register 2024)

Research origin

Univ. of Helsinki

Business ID

3414306-9 · Finnish trade register

Funding

€1M seed (Inventure, Almaral, Athensmed, University of Helsinki Funds + Business Finland grant)

Links

Where this sits on the map

MONCYTE Health is one of 33 companies in Therapeutics & Diagnostics. The others:

How this row was decided

Every row on this map is checked by hand against the trade register and the company's own material, and placed in the sector that best describes its business or its technology. Service firms and consultancies are left out, however advanced the technology they work with — the test is where the revenue comes from. Only funding figures the company or its investor has published are shown. The full rules are on the landscape ↗